Drug Profile
Sirotinib
Alternative Names: 5491; XZP 5491Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator XuanZhu Pharma
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Cancer in China